Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma
NCT03086993
Unknown
This study will evaluate two groups of patients who have intrahepatic cholangiocarcinoma. Each group will receive induction treatment with Cisplatin and Gemcitabine per SOC for 4 treatment cycles. Following induction treatment patients will be randomize (1:1), to 2 arms of treatment. One group (50%) will be receive high dose chemotherapy delivered specifically to the liver, while the other group (50%) will continue treatment with Cisplatin and Gemcitabine. Patient in each group will get repeatin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/23/2022
Locations: Duke Health, Durham, North Carolina +2 locations
Conditions: Bile Duct Cancer, Intrahepatic Cholangiocarcinoma
Register for Updates
Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM
NCT02838745
Terminated
Primary Objective To determine the maximum tolerated dose (MTD) of intrathoracic administration of pemetrexed when given in conjunction with cisplatin in patients with resectable malignant pleural mesothelioma MPM. Secondary Objectives To determine the toxicity and grades associated with cytoreductive surgery and Hyperthermic Intraoperative Chemotherapy HIOC with cisplatin and pemetrexed in patients with resectable MPM. To assess overall survival and progression-free survival after PD or EPP... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/15/2022
Locations: Baylor St Lukes, Houston, Texas
Conditions: Mesothelioma
Register for Updates
A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer
NCT02608684
Completed
To evaluate the efficacy and safety of anti-PD-1 antibody MK-3475 (pembrolizumab) in combination with gemcitabine and cisplatin chemotherapy in women with recurrent platinum-resistant ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/14/2022
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Ovarian Cancer
Register for Updates
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
NCT03770299
Withdrawn
The purpose of this study is to determine if nivolumab added to the standard of care therapy (SOC) given after surgery is more effective than SOC alone in prolonging disease free survival in NSCLC participants with minimal residual disease detected after surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/09/2022
Locations: Local Institution, Jacksonville, Florida +12 locations
Conditions: Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, Circulating Tumor DNA
Register for Updates
A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
NCT02662634
Withdrawn
Feasibility and Safety study of autologous dendritic cell immunotherapy (AGS-003-LNG) in patients with resectable non-small cell lung cancer.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
03/03/2022
Locations: Cancer Research Network of Nebraska / Oncology Associates, Omaha, Nebraska
Conditions: Non-small Cell Lung Cancer (NSCLC)
Register for Updates
Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer
NCT04061590
Withdrawn
This phase II trial studies how well pembrolizumab with or without chemotherapy works when given before surgery in treating patients with stage I-IIIA non-small cell lung cancer. Immunotherapy with pembrolizumab, may induce changes in body?s immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cisplatin and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from div... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2022
Locations: University of California, San Francisco, San Francisco, California
Conditions: Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
Register for Updates
Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
NCT03067610
Completed
Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/16/2022
Locations: Rush University Medical Center, Chicago, Illinois +1 locations
Conditions: Head and Neck Cancer, Carcinoma, Squamous Cell, Neoplasms, Oral, Neoplasms, Pharyngeal
Register for Updates
Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma
NCT01554410
Completed
The primary objective of the study is to identify the highest dose of gemcitabine that can be given safely with cisplatin and pelvic intensity modulated radiation therapy (IMRT) in women with locally advanced cervical cancer. The investigators hypothesis is that IMRT will reduce gastrointestinal and hematologic toxicity, permitting escalating doses of gemcitabine to be feasibly delivered in patients with locally advanced cervical cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/16/2022
Locations: Moores UC San Diego Cancer Center, La Jolla, California
Conditions: Cervical Carcinoma
Register for Updates
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
NCT01126749
Terminated
The purpose of this study is to determine whether Patients with Locally Advanced or Metastatic Bladder Cancer who receive Eribulin Mesylate Administered in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy is safety and tolerable when administered to patients with locally advanced or metastatic bladder cancer and to gain preliminary data on whether patients may benefit from this combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2022
Locations: Not set, Birmingham, Alabama +41 locations
Conditions: Bladder Cancer
Register for Updates
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors
NCT02723864
Completed
Background: The drug cisplatin treats certain cancers when given with other chemotherapy drugs. Researchers think combining cisplatin with 2 other drugs could block proteins that support cancer cell growth. The other drugs are ABT-888 (veliparib) and M6620 (VX-970). They want to test if this drug combination slows the growth of cancer and is safe. Objectives: To test the safety and tolerability of VX-970 and veliparib combined with cisplatin in people with advanced refractory solid tumors. To... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2022
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland +2 locations
Conditions: Neoplasms
Register for Updates
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
NCT00867178
Completed
This pilot clinical trial studies the side effects and the best way to give vorinostat with isotretinoin and combination chemotherapy and to see how well they work in treating younger patients with embryonal tumors of the central nervous system. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as isotretinoin, vincristine sulfate, cisplatin, cyclophosphamide, and etoposide phosphate, work in different ways to s... Read More
Gender:
ALL
Ages:
Between 2 months and 47 months
Trial Updated:
01/12/2022
Locations: Children's Hospital Los Angeles, Los Angeles, California +14 locations
Conditions: Medulloblastoma, Pineoblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified
Register for Updates
Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer
NCT00003777
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as amifostine may prevent the side effects of radiation therapy. Combining more than one drug and combining radiation therapy and surgery with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining surgery, radiation therapy, and combination chemotherapy... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
01/11/2022
Locations: University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania
Conditions: Head and Neck Cancer
Register for Updates